CLGN — COLLPLANT BIOTECHNOLOGIES LT
As of Q2 2026, 4 SEC-registered investment managers reported holding CLGN (COLLPLANT BIOTECHNOLOGIES LT) in their latest 13F filings, with a combined reported value of $40.55K across 116.24K shares. That is +135.5% by share count (+66.88K shares) versus the previous quarter, while reported value moved +53.4%. Ownership is concentrated: the five largest holders account for 100.0% of reported value and the top ten for 100.0%.
Compared with the prior quarter, 3 added to existing stakes, 1 exited entirely. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q2 2026, not real-time trading.
CLGN is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
| Fund | Quarter | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|---|
| ARK Invest history | Q2 2022 | 235.66K | $2.19M | 0.01% | Add |
| Renaissance Technologies history | Q2 2026 | 61.50K | $21.46K | 0.00% | Add |
| Citadel Advisors history | Q2 2026 | 53.70K | $18.74K | 0.00% | Add |
| PNC Financial Services history | Q2 2024 | 3.60K | $17.89K | 0.00% | Hold |
| Bank of America Corp history | Q4 2025 | 2.50K | $3.50K | 0.00% | Hold |
| JPMorgan Chase & Co history | Q4 2023 | 371 | $2.37K | 0.00% | New |
| UBS Group AG history | Q2 2026 | 1.03K | $361 | 0.00% | Add |
| Wells Fargo & Co history | Q1 2026 | 300 | $161 | 0.00% | Reduce |
| Morgan Stanley history | Q2 2026 | 1 | $1 | 0.00% | Hold |
New Positions (Q2 2026)
No fund opened a new position this quarter.
Fully Exited (vs previous quarter)
- Wells Fargo & Co sold 300 sh · $161
Fund Position History — shares by quarter (top 9 funds)
| Fund | Q3 2021 | Q4 2021 | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Renaissance Technologies | 10.00K | — | — | — | — | — | — | — | — | — | — | — | — | 10.60K | 10.30K | 41.60K | 21.90K | 17.60K | 16.80K | 61.50K |
| Citadel Advisors | — | — | 11.70K | — | — | — | — | — | — | 10.23K | 13.89K | — | — | — | — | — | — | — | 32.16K | 53.70K |
| UBS Group AG | — | 5.27K | 3.43K | 7.51K | 9.17K | 7.04K | 8.00K | 6.55K | 5.69K | — | 4.78K | 7.14K | 11.95K | 22.21K | 24.07K | — | — | — | 95 | 1.03K |
| Morgan Stanley | 50 | 721 | 250 | 50 | 173 | 171 | 171 | 121 | 121 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2.41K | 1 | 1 | 1 |
| Bank of America Corp | — | — | — | — | 4.80K | 4.80K | 7.39K | 7.39K | 7.30K | 7.30K | 7.30K | 7.30K | 2.83K | 2.50K | 2.50K | 2.50K | 2.50K | 2.50K | — | — |
| Wells Fargo & Co | — | — | 100 | — | — | — | — | — | — | — | — | — | 4.00K | 8.40K | 11.40K | 12.40K | 10.00K | 2.00K | 300 | — |
| ARK Invest | 191.29K | 165.45K | 228.66K | 235.66K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| JPMorgan Chase & Co | — | — | — | — | — | — | — | — | — | 371 | — | — | — | — | — | — | — | — | — | — |
| PNC Financial Services | — | 3.60K | 3.60K | 3.60K | 3.60K | 3.60K | 3.60K | 3.60K | 3.60K | 3.60K | 3.60K | 3.60K | — | — | — | — | — | — | — | — |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details